Decoy Therapeutics to Unveil AI Peptide Design Platform and New Preclinical Antiviral Data
Decoy Therapeutics will present on AI-driven de novo peptide design at two Boston conferences starting April 28 after partnering with Quantori to deploy a Google Cloud molecular simulation platform. Sessions include new preclinical data on its pan-coronavirus fusion inhibitor and a discovery-stage broad antiviral against influenza, COVID-19 and RSV.
1. Conference Engagements
Decoy Therapeutics executives will present at two Boston peptide therapeutics conferences the week of April 27. CBO Peter Marschel will lead a 60-minute roundtable on computational peptide design challenges at the Oligonucleotide & Peptides HubXchange on April 30, CSO Dr. Barbara Hibner and CTO Dr. Michael Lipp will co-present a Spotlight Case Study on peptide conjugate antiviral development at the Peptide-Based Therapeutics Summit on April 28, and advisor Dr. Bradley Pentelute will deliver the opening keynote on machine learning for drug discovery on April 29.
2. Quantori Partnership and AI Platform
The company recently partnered with Quantori to deploy a Google Cloud-native, AI-driven peptide design and molecular simulation platform. This collaboration aims to shorten the cycle from computational design to D-MAV candidate generation and advance de novo design beyond traditional ligand reengineering.
3. D-MAV Pipeline and Preclinical Data
Decoy’s D-MAV pipeline includes a preclinical pan-coronavirus fusion inhibitor and a discovery-stage broad antiviral targeting influenza, COVID-19 and RSV. Both programs leverage the IMP3ACT peptide conjugate platform, integrating AI-enabled design with rapid synthesis to support iteration across multiple viral families, with new preclinical data to be showcased.